A carregar...
Publicação
Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 10.22 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Cancer is the second leading cause of death in the world. Given that cancer is a highly individualized disease, predicting the best chemotherapeutic treatment for individual patients can be difficult. Ex vivo models such as mouse patient-derived xenografts (PDX) and organoids are being developed to predict patient-specific chemosensitivity profiles before treatment in the clinic. Although promising, these models have significant disadvantages including long growth times that introduce genetic and epigenetic changes to the tumor. The zebrafish xenograft assay is ideal for personalized medicine. Imaging of the small, transparent fry is unparalleled among vertebrate organisms. In addition, the speed (5-7 days) and small patient tissue requirements (100-200 cells per animal) are unique features of the zebrafish xenograft model that enable patient-specific chemosensitivity analyses.
Descrição
Palavras-chave
Zebrafish Bevacizumab Cancer therapy
Contexto Educativo
Citação
Commun Biol. 2020 Jun 10;3(1):299
Editora
Nature Publishing Group UK